Galectin Therapeutics Update on the Impact of COVID-19
02. April 2020 08:03 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the...
Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update
16. März 2020 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 16, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer
20. Februar 2020 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a leader in the field of NASH therapeutics, today announced the appointment of Pol F. Boudes, M.D. to the...
Galectin Therapeutics’ President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020
04. Februar 2020 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H....
Galectin Therapeutics’ Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
09. Dezember 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper...
Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis
05. Dezember 2019 12:05 ET
|
Galectin Therapeutics Inc.
Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study Dr. Harold Shlevin, CEO,...
Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders
26. November 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H....
Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit
18. November 2019 16:10 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer,...
Galectin Therapeutics Reports Q3 2019 Financial Results
12. November 2019 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis
11. November 2019 09:47 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration...